Australia - englanti - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - galantamine hydrobromide, quantity: 30.756 mg (equivalent: galantamine, qty 24 mg) - capsule, modified release - excipient ingredients: indigo carmine; iron oxide red; erythrosine; gelatin; hypromellose; magnesium stearate; titanium dioxide; iron oxide yellow; microcrystalline cellulose; ethylcellulose - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type

Australia - englanti - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - galantamine hydrobromide, quantity: 20.504 mg (equivalent: galantamine, qty 16 mg) - capsule, modified release - excipient ingredients: gelatin; ethylcellulose; titanium dioxide; microcrystalline cellulose; iron oxide red; magnesium stearate; hypromellose - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type

Australia - englanti - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - galantamine hydrobromide, quantity: 10.252 mg (equivalent: galantamine, qty 8 mg) - capsule, modified release - excipient ingredients: hypromellose; gelatin; magnesium stearate; microcrystalline cellulose; ethylcellulose; titanium dioxide - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type

Yhdysvallat - englanti - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - galantamine hydrobromide (unii: mj4ptd2vvw) (galantamine - unii:0d3q044kca) - galantamine 8 mg

Yhdysvallat - englanti - NLM (National Library of Medicine)

major pharmaceuticals - galantamine hydrobromide (unii: mj4ptd2vvw) (galantamine - unii:0d3q044kca) - galantamine tablets are indicated for the treatment of mild to moderate dementia of the alzheimer’s type. galantamine tablets are contraindicated in patients with known hypersensitivity to galantamine hydrobromide or to any excipients used in the formulation. risk summary there are no adequate data on the developmental risk associated with the use of galantamine tablets in pregnant women. in studies conducted in animals, administration of galantamine during pregnancy resulted in developmental toxicity (increased incidence of morphological abnormalities and decreased growth in offspring) at doses similar to or greater than those used clinically (see data). in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. the background risk of major birth defects and miscarriage for the indicated population is unknown. data animal data in rats, administration of galantamine (oral d

Kanada - englanti - Health Canada

pharmascience inc - galantamine (galantamine hydrobromide) - capsule (extended release) - 8mg - galantamine (galantamine hydrobromide) 8mg - parasympathomemetic (cholinergic) agents

Kanada - englanti - Health Canada

pharmascience inc - galantamine (galantamine hydrobromide) - capsule (extended release) - 16mg - galantamine (galantamine hydrobromide) 16mg - parasympathomemetic (cholinergic) agents

Kanada - englanti - Health Canada

pharmascience inc - galantamine (galantamine hydrobromide) - capsule (extended release) - 24mg - galantamine (galantamine hydrobromide) 24mg - parasympathomemetic (cholinergic) agents

Kanada - englanti - Health Canada

teva canada limited - galantamine (galantamine hydrobromide) - capsule (extended release) - 8mg - galantamine (galantamine hydrobromide) 8mg - parasympathomemetic (cholinergic) agents

Kanada - englanti - Health Canada

teva canada limited - galantamine (galantamine hydrobromide) - capsule (extended release) - 16mg - galantamine (galantamine hydrobromide) 16mg - parasympathomemetic (cholinergic) agents